Patch testing with the European baseline series and 10 added allergens: Single-centre study of 748 patients.
baseline series
clinical epidemiology
contact sensitization
patch testing
simultaneous reactivity
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
16
06
2022
received:
27
04
2022
accepted:
21
06
2022
pubmed:
24
6
2022
medline:
6
10
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co-reactivity of additional allergens. Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done. Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone-21-phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea and Compositae mix II need to be added to the EBS.
Sections du résumé
BACKGROUND
BACKGROUND
The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate.
OBJECTIVES
OBJECTIVE
We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co-reactivity of additional allergens.
METHODS
METHODS
Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done.
RESULTS
RESULTS
Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone-21-phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings.
CONCLUSION
CONCLUSIONS
We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2-bromo-2-nitropropane-1,3-diol, diazolidinyl urea and Compositae mix II need to be added to the EBS.
Identifiants
pubmed: 35736503
doi: 10.1111/cod.14178
pmc: PMC9796124
doi:
Substances chimiques
Allergens
0
Nitroparaffins
0
Phosphates
0
Propylene Glycols
0
Thimerosal
2225PI3MOV
Betaine
3SCV180C9W
cocamidopropyl betaine
5OCF3O11KX
Dexamethasone
7S5I7G3JQL
Urea
8W8T17847W
2-nitropropane
GKV234L2QH
diazolidinylurea
H5RIZ3MPW4
Propane
T75W9911L6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-446Informations de copyright
© 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
Références
J Eur Acad Dermatol Venereol. 2008 Feb;22(2):174-81
pubmed: 18211410
Contact Dermatitis. 2011 Jul;65(1):38-42
pubmed: 21309788
Contact Dermatitis. 2011 Dec;65(6):322-8
pubmed: 22077434
Br J Dermatol. 2008 Aug;159(2):379-86
pubmed: 18510664
Contact Dermatitis. 2019 Nov;81(5):368-373
pubmed: 31265134
Contact Dermatitis. 1999 Nov;41(5):241-50
pubmed: 10554056
Contact Dermatitis. 2021 Mar 21;:
pubmed: 33745196
Am J Contact Dermat. 2002 Mar;13(1):1-2
pubmed: 11887096
Contact Dermatitis. 1991 Jan;24(1):6-10
pubmed: 2044374
Ann Allergy Asthma Immunol. 2005 Jul;95(1):61-5
pubmed: 16095143
Contact Dermatitis. 2007 Oct;57(4):230-4
pubmed: 17868215
Contact Dermatitis. 2019 Apr;80(4):222-227
pubmed: 30378139
Contact Dermatitis. 2001 Mar;44(3):173-7
pubmed: 11217990
Br J Dermatol. 2009 May;160(5):946-54
pubmed: 19302065
Contact Dermatitis. 1995 Sep;33(3):145-8
pubmed: 8565452
Contact Dermatitis. 2010 Jan;62(1):18-31
pubmed: 20136876
Contact Dermatitis. 2021 Feb;84(2):95-102
pubmed: 32876992
Allergy. 2001 Dec;56(12):1192-6
pubmed: 11736749
Contact Dermatitis. 2022 Nov;87(5):439-446
pubmed: 35736503
Dermatitis. 2018 Nov/Dec;29(6):297-309
pubmed: 30422882
Contact Dermatitis. 2011 Nov;65(5):286-92
pubmed: 21767276
Contact Dermatitis. 1994 Oct;31(4):209-13
pubmed: 7842673
Dermatitis. 2015 Jan-Feb;26(1):49-59
pubmed: 25581671
Contact Dermatitis. 2003 May;48(5):286-7
pubmed: 12868983
Contact Dermatitis. 2009 Aug;61(2):63-85
pubmed: 19706047
Drugs. 2001;61(5):565-72
pubmed: 11368282
Contact Dermatitis. 2012 Jul;67(1):9-19
pubmed: 22500724
Contact Dermatitis. 2015 Oct;73(4):195-221
pubmed: 26179009
Contact Dermatitis. 2019 Jan;80(1):1-4
pubmed: 30421432